证券代码：002422 证券简称：科伦药业 公告编号：2025-087 四川科伦药业股份有限公司 关于预计公司与石四药集团 2026 年度日常关联交易情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、关联交易概述 （一）概述 四川科伦药业股份有限公司及其控制的公司（以下简称"公司"、"本公司" 或"公司及其下属企业"）与石四药集团有限公司及其子公司（以下简称"石四 药集团"）发生的关联交易是指公司与关联方石四药集团之间因采购、销售商品 和提供/接受服务等形成的日常关联交易。 根据《深圳证券交易所股票上市规则》第 6.3.3 条的规定，石四药集团为公 司关联法人。 公司 2026 年度与石四药集团之间的交易总额预计不超过 25,773 万元。公司 于 2025 年 12 月 23 日召开的第八届董事会第十次会议以 9 票赞成、0 票反对、0 票弃权审议通过了《关于预计公司与石四药集团 2026 年度日常关联交易情况的 议案》，不涉及应回避的董事。该议案不需要提交股东会审议，提交董事会前已 经公司独立董事专门会议审议通过。 | 关联交易类别 | 关联 ...

证券代码：002422 证券简称：科伦药业 公告编号：2025-088 四川科伦药业股份有限公司 关于预计公司 2026 年度部分日常关联交易情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、日常关联交易概述 （一）概述 本议案所涉公司日常关联交易是指四川科伦药业股份有限公司及子公司（以 下简称"公司"或"本公司"）与关联方华润科伦医药（四川）有限公司及其下 属子公司（以下简称"华润科伦"）发生的商品销售、材料采购、接受及提供劳 务，与关联方伊犁恒辉淀粉有限公司（以下简称"恒辉淀粉"）发生的委托加工 原材料和材料采购，与伊犁顺鸿生态农业科技开发有限公司（以下简称"伊犁顺 鸿"）发生的商品销售形成的关联交易。 华润科伦系公司董事、总经理刘思川先生担任董事的公司，根据《深圳证券 交易所股票上市规则》第 6.3.3 条的规定，华润科伦为公司关联法人。恒辉淀粉、 伊犁顺鸿系本公司董事、总经理刘思川先生控股的四川科伦兴川生物科技有限公 司（以下简称"科伦兴川"）控制的公司，根据《深圳证券交易所股票上市规则》 第 6.3.3 条的规定，恒辉淀粉、伊犁顺鸿为公 ...

四川科伦药业股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"或"科伦药业"）第八届董 事会第十次会议通知于 2025 年 12 月 19 日以电话和电子邮件方式送达全体董事 和高级管理人员。第八届董事会第十次会议于 2025 年 12 月 23 日以通讯的方式 召开，会议应到董事 9 人，实到董事 9 人，公司高级管理人员列席了会议。会议 的召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、行 政法规、部门规章、规范性文件和《公司章程》的规定，作出的决议合法有效。 证券代码：002422 证券简称：科伦药业 公告编号：2025-086 三、以 9 票同意、0 票反对、0 票弃权，审议通过了《关于修订<财务管理 制度>的议案》 为适应市场经济发展的需要，规范公司会计确认、计量和报告行为，保证会 计信息质量，使公司的会计工作有章可循、有法可依，公允地处理会计事项，以 提高公司经济效益，维护股东权益，公司根据《中华人民共和国会计法》《企业 财务通则》《会计基础工作 ...

Core Insights - Recent news highlights a surge in collective procurement (集采) activities in China, particularly in Henan province, where 34 high-demand and high-value drug varieties are set for a new round of procurement [1][17] - The national procurement signal indicates that over 140 drug varieties meet the competitive criteria of having seven or more companies, with notable participation from companies like Qilu, Yuanda, and Beite [1][13] Group 1: Procurement Details - The Henan provincial healthcare bureau has released a draft for the procurement of 34 drug varieties, focusing on alternatives that are high in usage and financial value [1][17] - The procurement list has been optimized, removing 15 drug varieties from the previous notification, indicating a refined focus on quality and market needs [3][20] - The procurement method categorizes oral solid preparations and injectables into two groups (A and B) based on quality, with specific selection criteria for each group [3][20] Group 2: Market Impact - The proposed procurement includes 10 Class A and 13 Class B drugs, with injectables dominating the list, reflecting a significant market shift [4][22] - The total sales for the selected drugs in Henan's public hospitals are projected to exceed 4 billion yuan in 2024 and 2 billion yuan in the first half of 2025 [10][28] - Notable drugs in the procurement list include Cisplatin and Erythromycin, both of which are essential in cancer treatment and infection management, respectively [6][24] Group 3: Competitive Landscape - The competitive landscape is expected to intensify, with companies like Qilu and Ruijun leading in market share for key products such as the analgesic Parecoxib, which is projected to have significant sales growth [10][28] - The sales of Ubenimex, an immune enhancer, have shown remarkable growth, with a projected increase of over 7779% in 2024, indicating strong market demand [7][25] - The overall sales scale in Henan's public hospitals has consistently remained above 15.8 billion yuan from 2021 to 2024, with a growth rate of 7.02% expected in the first half of 2025 [10][29]

Investment Rating - The industry investment rating is "Overweight" (maintained) [7] Core Insights - The report highlights the significant breakthrough of Fuhong Hanlin's PD-1 inhibitor, H drug, which has received acceptance for registration for perioperative treatment of resectable gastric cancer, marking a key advancement in tumor immunotherapy [7] - The global tumor immunotherapy market is projected to grow at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2031, indicating a substantial market opportunity as the treatment landscape expands from late-stage to early-stage therapies [7] - The report emphasizes the potential for A-share companies to benefit from this innovation, particularly those involved in tumor immunotherapy and related services [7] Summary by Sections Industry Performance - The industry has shown relative returns of -3.06% over the past month, -9.84% over the past three months, and -7.91% over the past year compared to the CSI 300 index [3] Recent Developments - The report discusses various recent developments in the pharmaceutical and biotechnology sector, including supportive policies in Sichuan and significant collaborations in the industry [4] Investment Recommendations - The report suggests focusing on "frontier breakthrough leaders" and "core assets in tumor innovation," recommending attention to companies such as Heng Rui Medicine, WuXi AppTec, and Kelun Pharmaceutical [7]

Investment Rating - The report maintains a focus on the innovative drug and medical device industry chain, indicating a high level of interest in this sector [1][6]. Core Insights - The innovative drug sector is experiencing high prosperity, with a recommendation to pay attention to pharmaceutical companies that are likely to see a revaluation of their value, such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][25]. - The report highlights the Biopharma/Biotech sector, which is expected to see performance improvements as innovative pipelines are realized, with companies like Innovent Biologics, BeiGene, and others being of particular interest [6][25]. - Attention is also drawn to CXO and upstream companies benefiting from innovation, including WuXi AppTec and WuXi Biologics [6][25]. - The report emphasizes the potential recovery of leading medical device companies such as United Imaging Healthcare and Lepu Medical [6][25]. Summary by Sections A-Shares Performance - In the third week of December 2025, the A-share pharmaceutical sector performed similarly to the overall market, with the Shanghai Composite Index rising by 0.03% and the SW Pharma and Biotech index falling by 0.1%, ranking 19th among Shenwan primary industries [8][10]. - Sub-sectors that performed relatively well included pharmaceutical commerce (+4.9%), medical equipment (+1.2%), and medical services (+0.5%) [10][25]. - Notable individual stock performances included Anhui Huaren Health Pharmaceutical Co., Ltd. (+55.9%), Luyan Pharma (+36.8%), and ShuYu Civilian (+35.7%) [13][25]. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Index down by 1.1% [19][25]. - In contrast, the U.S. pharmaceutical sector outperformed the market, with the S&P Healthcare Select Sector rising by 0.6% compared to the S&P 500's 0.1% increase [19][25].

Investment Rating - The industry investment rating is maintained at "Overweight" [5] Core Insights - The Sichuan provincial government has issued a comprehensive policy to support the high-quality development of the biopharmaceutical and medical device industries, addressing long-standing issues such as lengthy R&D cycles and market access challenges [5][7] - The policy includes 21 specific measures aimed at creating a full-chain innovation ecosystem, providing financial support for approved innovative drugs and medical devices, and significantly reducing approval times for product launches [5][7] - The policy is expected to benefit local leading enterprises with strong R&D capabilities, such as Baillie Tianheng and Kelun Pharmaceutical, by offering them financial and regulatory advantages [7] Summary by Sections Recent Industry Performance - The industry has shown relative returns of -1.87% over the past month, -9.27% over the past three months, and -6.57% over the past year compared to the CSI 300 index [3] Investment Highlights - The policy provides up to 15 million yuan in provincial financial support for Class 1 innovative drugs and up to 2 million yuan for innovative medical devices, reducing R&D risks and financial pressures for companies [7] - Approval times for drug applications have been significantly reduced, with technical review times for supplementary drug applications cut from 200 working days to 60, and for Class II medical devices to 35 working days [7] - The policy also facilitates market access by requiring the dynamic compilation of new and innovative drug and device directories, ensuring that hospitals can procure these products promptly [7]

Core Insights - The Chengdu-Chongqing region aims to establish a world-class advanced manufacturing cluster, focusing on electronic information and biomedicine, with a total scale exceeding 2.2 trillion yuan [1] Group 1: Collaborative Mechanisms - Sichuan has established a provincial mechanism for collaborative promotion of key industries, while Chongqing has implemented a "33618" modern manufacturing cluster system [1] - The two regions are jointly executing a three-year action plan to enhance the electronic information advanced manufacturing cluster [1] Group 2: Industry Chain Development - Sichuan and Chongqing are strengthening their industry chains in areas such as integrated circuits, new displays, and innovative pharmaceuticals, creating a supply-demand matching platform that has facilitated over 100 billion yuan in mutual orders [1] Group 3: Innovation and Infrastructure - The two provinces are jointly pursuing over 100 national-level innovation platforms, including the National Innovation Center for Ultra-High Definition Video and major scientific infrastructure for translational medicine [1] Group 4: Investment Opportunities - An investment opportunity list was released, covering 35 industrial parks in the Sichuan-Chongqing region, focusing on six key industries for precise supply-demand matching [2] - A specialized service capability list was compiled, detailing professional services in research, industry, and finance [2] Group 5: Biomedicine Initiatives - A list of 104 public service platforms in biomedicine was published, including 41 pilot testing platforms and 28 enterprise technology centers [2] - Five cross-regional cooperation projects were initiated, involving institutions like Sichuan University West China Hospital and companies such as Kelun Pharmaceutical and Boteng Pharmaceutical [2] Group 6: Electronic Information Sector - The first five service workstations for the electronic information advanced manufacturing cluster were inaugurated, and several projects focused on AI quality control in semiconductor processes were signed [3] - Key parks like Chongqing Xiyong Microelectronics Industrial Park and Sichuan Communication Industry Park are actively engaging in ecosystem cooperation [3]

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the sector [1]. Industry Summary - As of October 2025, the production of chemical pharmaceutical raw materials in China reached 313,000 tons, showing a year-on-year decrease of 1.6% [1]. - From January to October 2025, the cumulative production of chemical pharmaceutical raw materials was 3,049,000 tons, reflecting a cumulative growth of 1.3% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1].

Core Viewpoint - Kolun Pharmaceutical experienced a 2.16% increase in stock price on December 19, with a trading volume of 313 million yuan, indicating a notable market interest in the company [1]. Financing Summary - On December 19, Kolun Pharmaceutical had a financing buy amount of 11.95 million yuan and a financing repayment of 19.66 million yuan, resulting in a net financing buy of -7.71 million yuan [1]. - As of December 19, the total financing and securities lending balance for Kolun Pharmaceutical was 944 million yuan, with the financing balance at 937 million yuan, accounting for 1.85% of the circulating market value, which is above the 70th percentile of the past year [1]. - The securities lending aspect showed a repayment of 900 shares with no shares sold, and a securities lending balance of 6.48 million yuan, exceeding the 80th percentile of the past year [1]. Business Performance Summary - As of September 30, Kolun Pharmaceutical reported a total of 37,100 shareholders, an increase of 8.35% from the previous period, while the average circulating shares per person decreased by 7.70% to 35,200 shares [2]. - For the period from January to September 2025, Kolun Pharmaceutical achieved an operating revenue of 13.28 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 1.20 billion yuan, down 51.41% year-on-year [2]. - Since its A-share listing, Kolun Pharmaceutical has distributed a total of 6.90 billion yuan in dividends, with 3.59 billion yuan distributed over the past three years [2]. Institutional Holdings Summary - As of September 30, 2025, the top ten circulating shareholders of Kolun Pharmaceutical included notable institutions such as China Europe Medical Health Mixed Fund, which held 40.06 million shares, a decrease of 2.54 million shares from the previous period [3]. - Other significant shareholders included Hong Kong Central Clearing Limited with 34.73 million shares (down 5.26 million shares), and Industrial Bank's Frontier Medical Stock A with 20 million shares (down 700,880 shares) [3]. - The top ten shareholders saw a general trend of reduced holdings, with the exception of Guangfa Multi-Factor Mixed Fund, which maintained its holding at 24.23 million shares [3].